Trump could force drug companies to accept lower payments from Medicare for treatments administered in doctors' offices.

The merger allows Pfizer to move an obsolete business off the balance sheet while still generating multimillion-dollar cashflows.

Insys is the first drugmaker to seek bankruptcy protection from its creditors as a result of legal action related to the U.S. opioid epidemic.

The verdict signals that the public is willing to hold pharmaceutical executives accountable for the U.S. crisis.

Officials from seven pharmaceutical giants are scheduled to appear before the Senate Finance Committee to discuss soaring drug prices.

The trial of Insys Therapeutics Inc. CEO John Kapoor could serve as a test-drive for how jurors weigh claims of industry wrongdoing.

U.S. counties where doctors received high volumes of opioid marketing saw more prescriptions and, in turn, more overdose deaths, according to a new study.

The Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. Will it work?